PT - JOURNAL ARTICLE AU - Masserey, Thiery AU - Lee, Tamsin AU - Golumbeanu, Monica AU - Shattock, Andrew J AU - Kelly, Sherrie L AU - Hastings, Ian M AU - Penny, Melissa A TI - The influence of biological, epidemiological, and treatment factors on the establishment and spread of drug-resistant <em>Plasmodium falciparum</em> AID - 10.1101/2022.02.05.22270500 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.05.22270500 4099 - http://medrxiv.org/content/early/2022/02/07/2022.02.05.22270500.short 4100 - http://medrxiv.org/content/early/2022/02/07/2022.02.05.22270500.full AB - The effectiveness of artemisinin-based combination therapies (ACTs) to treat Plasmodium falciparum malaria is threatened by resistance. The complex interplay between sources of selective pressure – treatment properties, biological factors, transmission intensity, and access to treatment – obscures understanding how, when, and why resistance establishes and spreads across different locations. We developed a disease modelling approach with emulator-based global sensitivity analysis to systematically quantify which of these factors drive establishment and spread of drug resistance. Drug resistance was more likely to evolve in low transmission settings due to the lower levels of (i) immunity and (ii) within-host competition between genotypes. Spread of parasites resistant to artemisinin partner drugs depended on the period of low drug concentration (known as the selection window). Spread of partial artemisinin resistance was slowed with prolonged parasite exposure to artemisinin derivatives and accelerated when the parasite was also resistant to the partner drug. Thus, to slow the spread of partial artemisinin resistance, molecular surveillance should be supported to detect resistance to partner drugs and to change ACTs accordingly. Furthermore, implementing more sustainable artemisinin-based therapies will require extending parasite exposure to artemisinin derivatives, and mitigating the selection windows of partner drugs, which could be achieved by including an additional long-acting drug.Impact Statement Detailed models of malaria and treatment dynamics were combined with emulator-based global sensitivity analysis to elucidate how the interplay of drug properties, infection biology, and epidemiological dynamics drives evolution of resistance to artemisinin-based combination therapies. The results identify mitigation strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded under the Swiss National Science Foundation Professorship of Melissa Penny (PP00P3_170702).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe did not use individual participant-level data. Parameters values used in the model were informed from the literature as referred to in the main text or the supplementary file. The source code for OpenMalaria was developed using the C++ language and is available at https://github.com/SwissTPH/openmalaria. The analysis script was developed using the R software. All generated data and the code used for data analysis and visualization will be made available on request.